TAC3 and asthma: Importantly, given that there is no approved endotype-driven therapeutic agent targeting the non-type 2 mechanism [13,14], these clustering results are quite valuable in suggesting possible pathobiologic mechanisms underlying non-type 2 severe asthma, namely TAC2 and TAC3, which are partly associated with inflammasome and mitochondria, respectively.